Sexual health

Why M. Genitalium Is Getting Hard to Cure

Save

Mycoplasma genitalium doesn't show up on standard STI panels, and guidelines don't recommend testing for it unless symptoms persist after treatment for something else — a diagnostic gap that's let repeated, unnecessary antibiotic exposure quietly build resistance in the bacteria itself. Understanding that gap explains both why it's hard to catch and why it's gotten hard to cure.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why is Mycoplasma genitalium getting hard to cure?

Mycoplasma genitalium is hard to cure because resistance to the antibiotic class that used to clear it in a single step — macrolides, most commonly azithromycin — has become widespread enough that guidelines no longer recommend using it alone. Current treatment starts with a different antibiotic, doxycycline, followed by a second step chosen based on whether resistance testing shows the infection is still macrolide-sensitive or has become macrolide-resistant 1.

That two-step, test-guided approach exists because guessing wrong has consequences: giving a macrolide to an already-resistant infection doesn't just fail to cure it, it can make the resistant strain more dominant. Mycoplasma genitalium treatment with antibiotics now depends on that resistance check rather than a single fixed prescription, which is a meaningfully different — and slower — process than treating chlamydia or gonorrhea.

What is Mycoplasma genitalium, and why isn't it caught sooner?

What is Mycoplasma genitalium? It's a small bacterium, without a rigid outer cell wall, that infects the urethra and cervix and is recognized as a cause of persistent urethritis and cervicitis. That missing cell wall matters clinically: whole classes of antibiotics that work by attacking a bacterial cell wall simply don't touch it, which narrows the treatment options before resistance even enters the picture.

The quiet symptoms of M. genitalium are a big part of why it's hard to treat: infection is often mild or symptom-free, so it isn't caught early the way a painful, obvious infection would be. National guidance reflects this — testing for Mycoplasma genitalium isn't recommended as part of a routine, initial workup for urethritis or cervicitis, but is reserved for when symptoms persist after treatment for something else 1. That means a first round of standard treatment for presumed chlamydia or gonorrhea often happens before anyone specifically tests for or treats M. genitalium — and every unnecessary round of antibiotics is another chance for resistance to develop.

How the resistance problem echoes drug-resistant gonorrhea

Mycoplasma genitalium isn't the only bacterial STI running out of easy antibiotic options. The rise of drug-resistant gonorrhea follows a similar arc: Neisseria gonorrhoeae has developed resistance to nearly every antibiotic class used against it over the decades, to the point that CDC has designated drug-resistant gonorrhea an urgent public-health threat, with cephalosporins now the last broadly recommended class 2.

The mechanism is different in each organism, but the pattern is the same: broad or repeated antibiotic use gives resistant strains a survival advantage over sensitive ones, and once resistance is established in a population, it tends to spread rather than reverse. For Mycoplasma genitalium, macrolide resistance emerged largely because it was — and sometimes still is — treated presumptively, without a test to confirm the diagnosis or check resistance first.

How the two-step, resistance-guided treatment works

Current guidance lays out two paths depending on what resistance testing shows: for an infection that tests as macrolide-sensitive, doxycycline is followed by a macrolide; for one that's macrolide-resistant — or when resistance testing isn't available — doxycycline is followed by a different antibiotic class entirely, moxifloxacin 13. Starting with doxycycline in both paths helps reduce the bacterial load before the second, more targeted antibiotic takes over, which appears to improve how well that second step works.

This is also why a Mycoplasma genitalium diagnosis without resistance testing available leaves a clinician making an educated choice rather than a confirmed one — the same infection, treated at two different clinics without access to resistance testing, might reasonably get two different second-step antibiotics. That's a real limitation of current U.S. testing infrastructure, not a sign either choice was wrong.

What happens when treatment doesn't work the first time

When symptoms persist after a full course of the recommended two-step treatment, guidelines direct clinicians to retest rather than repeat the same antibiotics again, since repeating a treatment the infection has already shown it can survive mostly adds more selective pressure for resistance 1. Retesting can confirm whether the infection is truly still present, whether it's a different resistance pattern than initially assumed, or whether symptoms are actually being caused by something else entirely.

This is also where the Mycoplasma genitalium testing window matters: testing too soon after finishing treatment can pick up leftover bacterial genetic material from an infection that's already been cleared, producing a false sense that treatment failed. Spacing a follow-up test out appropriately after treatment ends gives a more reliable answer than testing immediately.

Why unnecessary antibiotic exposure makes this worse

Every course of an antibiotic that a bacterium survives is a chance for resistance to strengthen, which is why the diagnostic gap around Mycoplasma genitalium — testing only after something else has already been tried — has real downstream consequences. It isn't only mgen-specific treatment that matters here: doxycycline itself is now also used more broadly, including as doxy-PEP, a preventive dose taken after sex to reduce the risk of several bacterial STIs. Whether doxy-PEP is safe from an antibiotic-resistance standpoint — including whether broader, repeated doxycycline use could make Mycoplasma genitalium resistance worse — is an active question researchers are still working through, part of why doxy-PEP is recommended for specific higher-risk groups rather than as routine use for everyone.

None of this is a reason to avoid antibiotics when they're genuinely needed. It's a reason testing and resistance checks matter as much as the prescription itself, and why a clinician asking for a test before treating — rather than treating on suspicion alone — is doing the more careful thing, not the slower one.

Common questions

Yes, in most cases, though it can take two rounds of different antibiotics rather than one. Because macrolide resistance is common, treatment is typically guided by a resistance test when one is available, choosing the second antibiotic based on whether the infection is still expected to respond to it rather than guessing.

Most standard STI panels test for chlamydia, gonorrhea, syphilis, HIV, and sometimes trichomoniasis — not Mycoplasma genitalium, since routine testing for it isn't recommended unless symptoms persist after treatment for something else. Someone would generally need to ask specifically, or already have had treatment fail, for this test to be part of an evaluation.

It isn't reliably self-limiting the way some infections can be, and because it's frequently symptom-free, an untreated infection can persist and be passed to partners without anyone noticing. Antibiotic treatment, guided by resistance testing where possible, remains the standard path to clearing it rather than waiting to see if it resolves.

Not directly — a past infection doesn't change how a future, separate infection responds to antibiotics. But repeated or incomplete courses of the same antibiotic across a population is exactly the pattern that builds resistance over time, which is part of why testing and completing the full recommended course matters more than it might seem.

Many clinicians recommend that recent partners be tested and, if positive, treated using the same resistance-guided approach, since an untreated partner is a common source of reinfection. Because Mycoplasma genitalium is often symptom-free, a partner can test positive without ever having noticed anything themselves.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When Mycoplasma genitalium symptoms need prompt evaluation

  • —Pelvic pain with fever, which can indicate the infection has spread to the upper reproductive tract
  • —Testicular pain and swelling, which can indicate epididymitis
  • —Symptoms during pregnancy
  • —Symptoms that persist after completing two different rounds of resistance-guided treatment

Pelvic pain with fever, or testicular pain and swelling, needs same-day in-person evaluation in urgent care or an emergency department rather than waiting, since these can indicate a complication or a different condition entirely.

This article is educational and doesn't replace testing or a clinician's guidance; only a laboratory test can confirm Mycoplasma genitalium and any resistance pattern.

References

  1. 1.Centers for Disease Control and Prevention (2021). Mycoplasma genitalium - STI Treatment Guidelines. CDC STI Treatment Guidelines, 2021. linkSupports that M. genitalium testing is not recommended for an initial cervicitis/urethritis workup but is considered for persistent symptoms after empiric treatment, and the doxycycline-then-azithromycin (macrolide-sensitive) or doxycycline-then-moxifloxacin (macrolide-resistant) treatment approach.
  2. 2.Centers for Disease Control and Prevention (2024). Drug-Resistant Gonorrhea. CDC (cdc.gov/gonorrhea). linkSupports that Neisseria gonorrhoeae has developed resistance to nearly every antibiotic class used to treat it and is designated an urgent public-health threat, used here as an analogous example of antibiotic resistance in another bacterial STI.
  3. 3.Workowski KA, Bachmann LH, Chan PA, et al. (Centers for Disease Control and Prevention) (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, Vol. 70, No. 4. doi:10.15585/mmwr.rr7004a1 ✓Source of record for the 2021 comprehensive U.S. STI treatment recommendations, used here to date and contextualize the doxycycline-then-macrolide-or-moxifloxacin treatment approach for M. genitalium.

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library